← Back to Search

Tau PET Imaging for Frontotemporal Dementia (SLD3 Trial)

N/A

Recruiting

Led By Keith A Josephs, M.D.

Research Sponsored by Mayo Clinic

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Must be over the age of 18

Must present with a chief complaint of progressive impairment of speech/language or changes in behavior

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

SLD3 Trial Summary

This trial will help researchers learn more about how much tau is in the brains of patients with PPA.

Who is the study for?

This trial is for adults over 18 who primarily speak English and have progressive speech/language issues or behavior changes, fitting the criteria for Primary Progressive Aphasia or Frontotemporal Dementia. They need someone to independently assess their functioning but can't join if they have other illnesses causing similar symptoms, are pregnant/breastfeeding, mute/unintelligible speech, MRI contraindications like metal implants, severe claustrophobia, brain structure abnormalities or are on certain medications.Check my eligibility

What is being tested?

The study tests F-18 AV 1451's ability to detect tau protein in the brain which is linked with Primary Progressive Aphasia and Frontotemporal Dementia. It aims to understand the overall tau burden in patients' brains through PET scans.See study design

What are the potential side effects?

While not explicitly listed here, typical side effects of PET imaging agents like F-18 AV 1451 may include injection site discomfort, allergic reactions and temporary changes in taste.

SLD3 Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am over 18 years old.

Select...

I am experiencing worsening problems with my speech, language, or behavior.

Select...

I have been diagnosed with Primary Progressive Aphasia or Frontotemporal Dementia.

SLD3 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

The investigators will be looking at the amount of Tau protein in the brain of patients with PPA and FTD.

SLD3 Trial Design

1Treatment groups

Experimental Treatment

Group I: Tau PET Scan, F-18 AV 1451Experimental Treatment1 Intervention

All subjects will receive a Tau PET scan.

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Mayo ClinicLead Sponsor

3,209 Previous Clinical Trials

3,766,934 Total Patients Enrolled

Keith A Josephs, M.D.Principal InvestigatorMayo Clinic

Media Library

F-18 AV 1451 Clinical Trial Eligibility Overview. Trial Name: NCT02736695 — N/A

Primary Progressive Aphasia Research Study Groups: Tau PET Scan, F-18 AV 1451

Primary Progressive Aphasia Clinical Trial 2023: F-18 AV 1451 Highlights & Side Effects. Trial Name: NCT02736695 — N/A

F-18 AV 1451 2023 Treatment Timeline for Medical Study. Trial Name: NCT02736695 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is enrollment for this experiment currently accessible to participants?

"According to the information provided on clinicaltrials.gov, this trial is not currently enrolling patients; it was originally posted on July 1st 2016 and last edited April 7th 2022. However, there are 119 other studies actively seeking participants at this time."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia

Keith A. Josephs 2016. "Assessment of Hyperphosphorylated Tau PET Binding in Primary Progressive Aphasia and Frontotemporal Dementia". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02736695.

All > Aphasia > Frontotemporal Dementia